Increasing experimental evidence has demonstrated that sphingolipids are likely to have an important regulatory function in the cardiovascular system. Two sphingolipids released from activated platelets, and therefore of particular relevance, are S1P (sphingosine 1-phosphate) and SPC (sphingosylphosphocholine). Both S1P and SPC can act as vasoconstrictors and may modulate VSMC (vascular smooth muscle cell) phenotype, as observed during the pathogenesis of vascular disease. Recent research has suggested that SPC may act as a pro-inflammatory mediator in VSMCs and, in some circumstances, may also contribute to the development of vascular disease.
S1P (sphingosine 1-phosphate) and the cardiovascular system
Sphingolipids, derived from sphingomyelin metabolism, have been implicated as potentially important mediators of cardiovascular function [1] . Predominantly, research has focused on the role of S1P, formed via the actions of sphingosine kinase. The in vivo source of S1P with most relevance to the cardiovascular system is likely to be platelets. Platelets do not express S1P lyase, an enzyme that regulates S1P breakdown, and therefore accumulate this sphingolipid [2] . During platelet activation, S1P is released and concentrations in serum have been estimated to reach the upper nanomolar/low micromolar range. Evidence indicating an important physiological role for sphingolipids was provided by the discovery of S1P-selective receptors [3, 4] . Five members of this seventransmembrane G-protein-coupled receptor family have now been cloned (S1P 1 -S1P 5 ), and at least three subtypes are expressed in VSMCs (vascular smooth muscle cells) [5] . These receptors are linked to various signalling pathways [6] . Evidence for the importance of S1P receptors in vascular function was demonstrated in S1P 1 −/− mice where a critical role in vascular development was uncovered [3] . Although S1P clearly has intracellular effects via a selective S1P-receptoractivated transduction system in VSMCs, its physiological and/or pathological relevance is still not entirely clear. In blood vessels, several studies have demonstrated that S1P can act as a vasoconstrictor dependent on the vascular bed [1, 5] , although the in vivo role of this effect remains to be determined.
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SPC (sphingosylphosphocholine) and the cardiovascular system
Another naturally occurring and structurally related sphingolipid that can act as a weak agonist at S1P receptors is SPC [7] . SPC is formed from sphingomyelin via the actions of a specific enzyme, sphingomyelin deacylase [7] . Although SPC and S1P have several common characteristics, less is known about SPC. Similar to S1P, SPC is increased in serum and is therefore likely to be released from activated platelets [8] . SPC can also induce vasoconstriction via similar intracellular mechanisms to S1P [1] . For example, in cerebral arteries, both S1P-and SPC-induced vasoconstriction is via an increase in [Ca 2+ ] i (intracellular Ca 2+ concentration), although the source of Ca 2+ differs (S1P liberates Ca 2+ from intracellular stores, whereas SPC predominantly activates an influx of extracellular Ca 2+ ) [5, 9] . In addition, S1P and SPC activate the monomeric GTP-binding protein RhoA, also involved in a vasocontractile response via inhibition of the smoothmuscle myosin phosphatase [5, 10] . Such similarities and a potentially similar mode of action via S1P receptors have led to the possibility that SPC may have a similar physiological role in blood vessels compared with S1P. Speculation that SPC effects are not necessarily mediated via S1P receptors was provided by initial studies, which identified putative high-affinity SPC receptors unrelated to the S1P receptor. However, subsequent investigation revealed that these proteins were not SPC-selective [11] . So far, no alternative SPC-selective membrane receptors have been identified and a direct intracellular action cannot be ruled out.
Sphingolipid and vascular disease
In addition to the regulation of vascular tone, sphingolipids may also have effects on VSMC phenotype. In cultured VSMCs, both S1P and SPC can activate intracellular pathways and gene expression typically associated with proliferation [1, 3, 7] . This may be indicative of a mitogenic response in vivo and potentially could indicate a role in the pathogenesis of vascular disease. Indeed, the mode of exposure to S1P and SPC via release from activated platelets with other known mitogens (such as platelet-derived growth factor) suggests this may be case. In contrast, recent work has also demonstrated that the S1P and SPC may contribute to an antiatherogenic action. In addition to being released by platelets, S1P and SPC are also lipid constituents of plasma lipoproteins [12, 13] . Both these sphingolipids are most abundant in HDL (high-density lipoprotein) compared with LDL (low-density lipoprotein). Some of the atheroprotective effect of HDL may be due to the sphingolipid content [12, 13] . This effect is predominantly via endothelial cells. The sphingolipid components produce this protective action by several mechanisms including decreasing endothelial cell apoptosis (thereby enhancing cell survival) and increasing nitric oxide production. Therefore there appears to be two different and apparently contradictory effects of sphingolipids with regard to blood vessel regulation. One effect on endothelial cells is antiatherogenic, while the other effect on VSMCs is pro-atherogenic. This suggests that the overall effect of sphingolipids in the cardiovascular system is dependent on the in vivo environment. High levels of plasma HDL would lead to a protective effect on endothelial cells, whereas destruction of the endothelial layer, by for example angioplasty, would result in direct exposure of VSMCs to S1P/SPC and a potential mitogenic effect. In addition, blood vessel aneurysm, such as subarachnoid haemorrhage from cerebral arteries, would lead to platelet recruitment with subsequent activation and release of S1P and SPC at the site of haemorrhage. The physiological role in the short term in this case may involve vasoconstriction, which would tend to decrease the haemorrhage. Longer-term effects of sphingolipids following haemorrhage are not known.
Although both S1P and SPC can induce similar effects in VSMCs in vitro, such as vasoconstriction and a potentially mitogenic action, we have recently shown that these sphingolipids may have divergent roles in VSM. In denuded rat cerebral arteries, S1P activated ERK1/2 (extracellularsignal-regulated kinase 1/2), but did not activate p38MAPK [p38 MAPK (mitogen-activated protein kinase)] or JNK (c-Jun N-terminal kinase) [9] . However, SPC increased activation of only p38MAPK, but not ERK1/2 or JNK. This observation has important implications as p38MAPK is often associated with an inflammatory response. Therefore SPC, but not S1P, may act as a pro-inflammatory mediator in VSMCs. Recently, studies in other cell types have indicated that SPC may have an inflammatory role. For example, in dendritic cells, SPC has been shown to up-regulate interleukin production as part of an inflammatory process [14] . Our group has recently shown in cultured VSMCs that SPC activates two transcription factors typically associated with inflammation, NF-κB (nuclear factor κB) and C/EBPs (CCAAT/enhancer-binding proteins), and leads to up-regulation of inflammatory chemokines (F. Mathieson, I. Hunter and C.F. Nixon, unpublished work). This occurs via a p38MAPK-dependent pathway. As vascular disease is known to have an important inflammatory component, SPC may therefore have an additional inflammatory role in vivo that could contribute to vascular pathology.
Conclusion
In summary, S1P and SPC have similar roles in vivo with respect to VSMCs. This includes vasoconstriction, which could contribute part of a physiological response during aneurysm and, following loss of the endothelial layer, a potentially mitogenic effect. Recent studies have also suggested some divergence of sphingolipid actions. In particular, SPC, but not S1P, may act as a pro-inflammatory mediator in VSM and through this action may augment the development of vascular disease.
